AAVantgarde closed a $141 million Series B, led by Amgen Ventures, to advance gene‑therapy programs for inherited retinal diseases. The Milan‑based biotech will deploy the financing to accelerate IND‑enabling studies and scale manufacturing capabilities for ocular AAV candidates. Investors cited the company’s retinal platform and clinical strategy as de‑risked assets in a competitive gene‑therapy field. The round positions AAVantgarde to move lead programs toward first‑in‑human testing while expanding CMC capacity. The financing highlights continued investor appetite for targeted rare‑disease gene therapies where delivery to a defined organ (the eye) improves translational predictability.